id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S6623 R18197 |
Burja (Valproate) (Controls unexposed, disease free), 2006 | Intracranial hemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No |
41.20 [2.24;756.57] C excluded (control group) |
1/2 5/211 | 6 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6619 R18177 |
Burja (Valproate) (Controls unexposed, sick), 2006 | Intracranial hemorrhage | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 15.00 [0.66;339.57] C | 1/2 2/32 | 3 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6687 R18658 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Periventricular haemorrhage (germinal layer) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [1.00;15058.31] C excluded (control group) |
0/1 0/62 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6695 R18819 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Periventricular haemorrhage (germinal layer) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.12;1923.88] C | 0/1 0/8 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 15.00 [1.09;206.94] | 3 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick; 2: Valproate) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6687, 6623